Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
Public ClinicalTrials.gov record NCT01777555. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an outpatient (i.e., at home) and in the clinic.
Study identification
- NCT ID
- NCT01777555
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 89 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2013
- Primary completion
- Dec 31, 2013
- Completion
- Dec 31, 2013
- Last update posted
- Aug 7, 2018
2013 – 2014
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Civitas Investigational Site 1013 | Little Rock | Arkansas | 72201 | — |
| Civitas Investigational Site 1004 | Boca Raton | Florida | 33427 | — |
| Civitas Investigational Site 1002 | Port Charlotte | Florida | 33948 | — |
| Civitas Investigational Site 1015 | Tampa | Florida | 33601 | — |
| Civitas Investigational Site 1007 | Kansas City | Kansas | 66101 | — |
| Civitas Investigational Site 1010 | Boston | Massachusetts | 02108 | — |
| Civitas Investigational Site 1001 | Bingham Farms | Michigan | 48025 | — |
| Civitas Investigational Site 1008 | Roseville | Michigan | 48066 | — |
| Civitas Investigational Site 1009 | Saint Louis | Michigan | 48880 | — |
| Civitas Investigational Site 1005 | West Bloomfield | Michigan | 48322 | — |
| Civitas Investigational Site 1011 | Kingston | New York | 12401 | — |
| Civitas Investigational Site 1014 | Cleveland | Ohio | 44101 | — |
| Civitas Investigational Site 1003 | Kirkland | Washington | 98033 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01777555, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2018 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01777555 live on ClinicalTrials.gov.